The permission to file an IND allows the company to design a proof-of-concept study in COVID-19 patients evaluating clinical doses of FSD-20. The primary endpoint of the study is to determine if adding FSD-201 to the standard of care will significantly improve the time to symptom relief.
Key secondary objectives include additional benefit in terms of safety, and length of time in the improvement of oxygen saturation, among others.
The company said the therapeutic effects of ultramicronized palmitoylethanolamide are supported by more than 600 scientific papers.
Price: 6.8000, Change: +3.70, Percent Change: +119.35
|Sector Update: Consumer|
|Sector Update: Financial|
|Sector Update: Energy|
|Midday Report: US Stocks Buoyed as Q2 Earnings, Vacc...|
|Forward Air Launches Less-Than-Truckload Service in ...|